Last $29.24 USD
Change Today -0.24 / -0.81%
Volume 456.9K
EBS On Other Exchanges
New York
As of 8:04 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Adam R. Havey

Executive Vice President and President of Biodefense Division, Emergent BioSolutions, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

As of Fiscal Year 2013


Mr. Adam R. Havey has been the President of Biodefense Division and Executive Vice President of Emergent BioSolutions, Inc. since March 2011. Mr. Havey served as an Executive Vice President of BioDefense Division of Emergent BioSolutions, Inc. since March 2011. He served as the President of Emergent BioDefense Operations Lansing LLC from January 2009 to February 2011 and Vice President of Business Operations from November 2007 to December 2008, Senior Director of Manufacturing ...

Read Full Background

Corporate Headquarters*

2273 Research Boulevard
Rockville, Maryland 20850

United States

Phone: 301-795-1800
Fax: 301-795-1899

Board Members Memberships*

There is no Board Members Memberships data available.


Bachelor's Degree
Michigan State University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$474,831

Stock Options*

Restricted Stock Awards$175,145
All Other Compensation$7,650
Exercisable Options50,674
Exercisable Options Value$197,785
Unexercisable Options40,445
Unexercisable Options Value$268,648
Total Value of Options$466,432
Total Number of Options91,119

Total Compensation*

Total Annual Cash Compensation$482,481
Total Short Term Compensation$474,831
Other Long Term Compensation$182,795
Total Calculated Compensation$805,364
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $29.24 USD -0.24


Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
William S. Marth Chief Executive Officer, President and Director
Albany Molecular Research Inc.
Peter William Grant Chief Executive Officer and Executive Director
Skyepharma PLC
567.0K GBP
Paul Chaplin MSc, Ph.D.Chief Executive Officer and President
Bavarian Nordic A/S
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at